Discontinuation of Etanercept After Successful Treatment in Patients with Juvenile Idiopathic Arthritis: Figure 1.
Authors:
- Agustin RemesalARAgustin Remesal
- Jaime DE InocencioJIJaime DE Inocencio
- Rosa MerinoRMRosa Merino
- Julia Garcia-ConsuegraJGJulia Garcia-Consuegra
- 1 September 2010
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 37 (9) , 1970-1971
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Discontinuation of etanercept in patients with rheumatoid arthritis who were in clinical remissionClinical Rheumatology, 2009
- Long‐term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritisArthritis & Rheumatism, 2009
- Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritisJoint Bone Spine, 2009
- When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritisAnnals of the Rheumatic Diseases, 2009
- Long‐term safety and efficacy of etanercept in children with polyarticular‐course juvenile rheumatoid arthritisArthritis & Rheumatism, 2006
- Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximabArthritis Research & Therapy, 2005
- Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitisRheumatology, 2004
- Six‐month results of a double‐blind, placebo‐controlled trial of etanercept treatment in patients with active ankylosing spondylitisArthritis & Rheumatism, 2003